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Previous  evidence  (1)  of  immunological  relationship  between  a 
variety  of Saccharomyces  cerevisiae  and  the  Type II  Pneumococcus 
consisted in the inter-reactions  of the yeast and the bacteria in the 
antisera produced by immunization  of rabbits with the two different 
microorganisms.  This paper reports the active immunization of mice 
against Type II pneumococci by vaccination with yeast. 
A  group of mice were vaccinated with heated suspensions of yeast 
cells, and tested for active immunity by subsequent injection of viru- 
]ent Type II Pneumococcus.  Because of the known  (2) irregularity 
in the active ~mmunity  responses of individual  mice to homo]ogous 
vaccination  with Type II pneumococci, it  seemed best to  base the 
imThunity tests of the yeast-vaccinated mice upon the percentage of 
animals surviving the test injection of a uniform dose of the Type II 
bacteria.  In order to show that the protection afforded by vaccina- 
tion with the yeast was not non-specific, groups of yeast-vaccinated 
mice were tested against comparable doses of Types I and III,  as well 
as against Type II pneumococci. 
~EXPERIM-~,NTAL 
Methods: A group of 100 white mice of approximately the same age and weight 
were injected subcutaneously at 2 day intervals with 0.5 cc. of a 0.1 per cent. 
suspension of the dried yeast cells (boiled 5 minutes);  after  12 subcutaneous in- 
jections and  a  rest of 3  days,  two intraperitoneal  injections were given.  The 
active irnmuI~ty  tests were made on the 92 surviving mice 12 days after the last 
immunization injection. 
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The yeast-vaccinated animals were divided into three groups: 57 to be tested 
against Type II pneumococci, 20 against Type I, and 15 against Type III pneu- 
mococci.  A uniform dosage  of  100  times  the minimum required  for death of 
normal mice was employed for the tests with  the three types of pneumococci. 
The quantitative sufficiency of the test doses was controlled  by injecting  groups 
of normal mice with each culture.  The test strains were highly virulent for mice; 
the cultures  used were inoculated  directly from the heart's blood of mice.  The 
results are presented  in Table I. 
The results (Table I) showed that 20 of 57, or 34  per  cent of  the 
mice vaccinated with yeast were protected against  subsequent  in- 
fection with 100 lethal doses of virulent Type II pneumococci.  The 
uniform deaths in the control group of non-vaccinated mice proved 
that the infection test dose was sufficient to eliminate any irregularities 
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due to the possible occurrence of individual mice possessing unusual 
natural  immunity against  the Type II bacteria.  Hence, the vac- 
/  o  cinated mice that survived can be considered to have acquired their 
immunity against Type II pneumococci by virtue of their vaccination 
with yeast.  Active immunity against Type II pneumococci is not 
easily obtained by mice even when vaccinated with the pneumococci 
themselves; and it is interesting to note that the percentage of in- 
dividual mice that obtained anti-Type II immunity in response to the 
yeast vaccination is about the same as the percentage of mice that 
obtain immunity in  response  to  homologous vaccination  with  the 
Type II bacteria  (2).  The uniform death of the yeast-vaccinated 
mice tested against Types I  and III pneumococci is important evi- JOHN  ~].  SUGG,  LURLINE  V.  RICHARDSON~  AND  JAMES  M.  NEILL  58i 
dence that  the protection  conferred by the yeast vaccination was 
specific to the Type II Pneumococcus. 
COMME.NT 
The  described protection of mice indicates that these animals 
respond to yeast antigen with production of antibodies specifically 
reactive with Type II pneumococd.  It had been shown  (i) that 
rabbits can respond to the same yeast antigen with production of 
antibodies that agglutinate  Type II bacterial  cells,  precipitate  Type 
II culture filtrates,  and confer passive protection against Type II 
infection; the more responsive rabbits yielding sera comparable in 
anti-Type II potency to the antisera  produced by immunization with 
the Type II bacterial  ceils  themselves.  In another study (3) it was 
found that the relative  antigenic  effectiveness  of two related  strains 
of pneumococd  differed  in different  species  of animals.  The present 
report therefore,  is of interest  as evidence that the immunological 
relationship  between the yeast and Type II  pneumococci causes  mice, 
as well as rabbits, to respond to yeast antigen with production of 
antibodies  specifically reactive with  the  Type  II  variety of 
Pneumococcus. 
S~ARY 
Mice vaccinated  with yeast were protected against subsequent 
infection  with Type II pneumococci, but not against Types I or III. 
While the protection was not universal,  as high a percentage of  mice 
acquired active  anti-Type II immunity, as was obtained by vaccina- 
tion  of another group of mice with Type II pneumococci themselves. 
This specific  protection  of  mice by active  immunization with the  yeast 
antigen, is probably due to the same immunological  relationship 
responsible for the anti-Type II reactivity  of the antisera  of rabbits 
immunized with yeast antigen. 
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